Atlas market file · Equity · United States
Fulgent Genetics, Inc.FLGT
- Last close
- 18.55
- Change
- +0.11%
- 96-bar range
- 14.04 – 21.59
- As of
- 6 Aug 2026
Fulgent Genetics, Inc. is a services-medical laboratories issuer listed as FLGT on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
FLGT
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-22.06% over the window).
Source rail: Yahoo Finance chart API (FLGT). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for FLGT. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
FLGT public profile
Services-medical laboratories issuer. Fulgent Genetics, Inc. is connected to current market context, cited company sources and its retained research file.
Fulgent Genetics, Inc. trades as FLGT on NASDAQ. Fulgent Genetics, Inc. (FLGT) has a latest verified close of 18.55, up 0.11%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files FLGT under USA Stocks and Science & Biotech Stocks for browsing.
What changed for Fulgent Genetics, Inc. today
Fulgent Genetics (FLGT) reported $71.1M in Q1 2026 revenue but swung to a $24.8M net loss, highlighting a growing chasm between its laboratory services growth narrative and financial reality. The company’s operating loss deepened to $34.6M as R&D expenses surged to $14.2M, raising eyebrows amid a cash balance of just $23.4M.
At its core, Fulgent operates two businesses: a clinical lab offering testing services interpreted by physicians, and a therapeutic development arm targeting genetic research. The lab services segment drives revenue, but the therapeutic pipeline remains speculative, with no approved products yet disclosed. This duality creates tension between near-term financial pressures and long-term R&D bets.
Recent SEC filings reveal aggressive equity incentives despite red ink. A June 2026 proxy statement detailed a new equity plan authorizing 3.5M shares for executives, even as the company burned $7.1M in operating cash. Investors might question whether this dilution is a vote of confidence or a lifeline for management.
The stock’s volatility could escalate following Fulgent’s ASCO 2026 abstract release, which hinted at promising oncology data but lacked concrete commercial timelines. Without a near-term catalyst, the market may focus on liquidity risks: cash reserves cover just 1.6 months of R&D spend at current rates.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
FLGT technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on FLGT
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep FLGT research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
FLGT FAQ
What is Fulgent Genetics, Inc. (FLGT)?Fulgent Genetics, Inc. (FLGT) has a latest verified close of 18.55, up 0.11%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Fulgent Genetics, Inc. (FLGT) has a latest verified close of 18.55, up 0.11%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for FLGT?Fulgent Genetics, Inc. (FLGT) has a latest verified close of 18.55, up 0.11%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Fulgent Genetics, Inc. (FLGT) has a latest verified close of 18.55, up 0.11%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files FLGT under USA Stocks and Science & Biotech Stocks for browsing.
How often is the FLGT page updated?The FLGT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The FLGT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for FLGT?The FLGT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:FLGT. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The FLGT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:FLGT. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on FLGT?Yes. The workstation can open FLGT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open FLGT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this FLGT page investment advice?No. The FLGT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The FLGT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →